Finerenone for heart failure with preserved pumping function
Part of Heart & circulation clinical trials.
This trial tests a new medicine called finerenone to see if it can reduce heart scarring and improve heart function in people with a certain type of heart failure (preserved ejection fraction). If you qualify, you may help researchers learn if this treatment can help you feel better and stay out of the hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have heart failure symptoms (like shortness of breath or swelling) and have had a recent flare-up that required a hospital visit or stronger water pills within the last 3 months.
- Your heart's pumping ability is at least 40% on a recent echocardiogram (heart ultrasound).
- A blood test shows elevated heart strain markers (NT-proBNP).
- A special heart MRI shows evidence of scarring (fibrosis) in the heart muscle.
- You can stop certain heart medicines (like spironolactone or eplerenone) for 4 weeks before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
This trial tests whether finerenone can improve heart muscle thickening in patients with certain heart or kidney risk factors. It may help reduce heart strain and improve heart function.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
This study tests a new drug called finerenone to see if it can improve heart function in people with a type of heart failure where the heart pumps normally but is stiff. It may help reduce symptoms and improve quality of life.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.